Skip to content
Specimen Atlas of Research Peptides82 plates · MIT
PeptidesDBan atlas

The record

Corrections

A public record of every fix is a trust asset, not a scandal.

When the atlas is wrong, the fix is logged here — dated, with what triggered it. A fabricated citation is not silently swapped out; it is removed and recorded. The methodology describes the checks that surface these in the first place.

  1. 2026-07-05Fabricated-citation audit

    Removed a fabricated citation (clarke-2018)

    A reference keyed clarke-2018 was cited three times on the tesamorelin plate for its glucose and insulin-sensitivity claims. No matching paper could be found in PubMed; the registry note flagged it as likely fabricated. It has been purged from the citation registry and from every plate. The two metabolic-outcome claims now cite Stanley et al. (JAMA, 2014; PMID 25038357), a real tesamorelin randomized trial; the glucose-intolerance safety claim now cites the FDA EGRIFTA label.

  2. 2026-07-05Citation cross-check

    Corrected a mismatched PMID (jastreboff-2023-reta)

    The retatrutide reference jastreboff-2023-reta carried the PubMed ID of a NEJM correspondence letter (37888926) rather than the primary Phase 2 trial it describes. The ID was corrected to 37366315 (Jastreboff et al., NEJM, 2023), which reports the 24.2% body-weight reduction the plate cites. The retatrutide headline stats, previously uncited, now point to it.